- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Chronic obstructive pulmonary disease
- Meeting Date: March 2022
- Public Summary Document (PSD) March 2022 PBAC Meeting - (PDF 722KB)
- Public Summary Document (PSD) March 2022 PBAC Meeting - (Word 133KB)
Beclometasone with formoterol – March 2022
Beclometasone with formeterol: Pressurised inhalation containing beclometasone dipropionate 100 micrograms and formoterol fumarate dihydrate 6 micrograms per dose, 120 dose; Fostair®
Last updated
1 July 2022